Holen Sie sich die Stockscreener-App
23.40
1.52%
0.3552
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
When (BBIO) Moves Investors should Listen - Stock Traders Daily
BBIO (BridgeBio Pharma) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Insider Sell Alert: Brian Stephenson Sells Shares of BridgeBio P - GuruFocus.com
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $613,825 in stock - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 - Investing.com
BridgeBio Pharma CFO Brian Stephenson sells shares worth $93,136 By Investing.com - Investing.com UK
Bridge Bio Study Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes in ATTR-CM - DocWire News
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Yahoo Finance
399,781 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by First Turn Management LLC - MarketBeat
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be - Simply Wall St
Royce & Associates LP Invests $3.11 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace
Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire
BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian
BridgeBio Pharma Announces Publication in the New England - GlobeNewswire
BBIO FY2024 EPS Estimate Reduced by Cantor Fitzgerald - MarketBeat
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $47.57 Average Price Target from Brokerages - MarketBeat
Scotiabank Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $45.00 - MarketBeat
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks
BridgeBio Pharma Inc (BBIO) Quarterly 10-Q Report - Quartzy
No-Moat BridgeBio's Valuation Driven by Pending Approval of Acoramidis; Positive Long-Term Outlook - Morningstar
BridgeBio Pharma Inc Reports Q3 2024 Revenue of $2.7 Million, Mi - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates - MSN
BridgeBio Pharma earnings beat by $0.13, revenue topped estimates - Investing.com UK
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic - Barchart
Achondroplasia Market to Show Remarkable Growth Trends from - openPR
BridgeBio Pharma: Q3 Earnings Snapshot - San Antonio Express-News
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - The Manila Times
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):